Rate of admission during ED stay · patients with vomiting related to acute gastroenteritis with mild to moderate dehydration
Oral ondansetron (weight based) probably leads to lower rate of admission during ED stay compared with placebo (moderate certainty).
1 finding from 1 review
Adverse events · patients with vomiting related to acute gastroenteritis with mild to moderate dehydration
1 finding from 1 review
Rate of admission 72 hrs · patients with vomiting related to acute gastroenteritis with mild to moderate dehydration
Oral ondansetron (weight based) showed no clear difference in rate of admission 72 hrs compared with placebo (low certainty).
2 findings from 1 review
Time to cessation of vomiting · patients with vomiting related to acute gastroenteritis with mild to moderate dehydration
1 finding from 1 review
Rate of intravenous rehydration during ED stay · patients with vomiting related to acute gastroenteritis with mild to moderate dehydration
Oral ondansetron (weight based) probably leads to lower rate of intravenous rehydration during ED stay compared with placebo (moderate certainty).
1 finding from 1 review
Rate of intravenous rehydration up to 72 hrs following discharge from ED (best ‐ worst scenario) · patients with vomiting related to acute gastroenteritis with mild to moderate dehydration
Oral ondansetron (weight based) may leads to lower rate of intravenous rehydration up to 72 hrs following discharge… compared with placebo (low certainty).
1 finding from 1 review
Rate of intravenous rehydration up to 72 hrs following discharge from ED (worst ‐ best scenario) · patients with vomiting related to acute gastroenteritis with mild to moderate dehydration
Oral ondansetron (weight based) may leads to lower rate of intravenous rehydration up to 72 hrs following discharge… compared with placebo (low certainty).
1 finding from 1 review
Proportion of patients with cessation of vomiting · patients with vomiting related to acute gastroenteritis with mild to moderate dehydration
Oral ondansetron (weight based) probably leads to higher proportion of patients with cessation of vomiting compared with placebo (moderate certainty).
1 finding from 1 review
Revisit rate · patients with vomiting related to acute gastroenteritis with mild to moderate dehydration
Oral ondansetron (weight based) showed no clear difference in revisit rate compared with placebo (low certainty).
1 finding from 1 review
Induction of clinical remission (CDAI < or = 150) · induction of remission in Crohn's disease
GM‐CSF showed no clear difference in induction of clinical remission (CDAI < or = 150) compared with placebo (low certainty).
1 finding from 1 review
Induction of 100‐point clinical response · induction of remission in Crohn's disease
GM‐CSF showed no clear difference in induction of 100‐point clinical response compared with placebo (low certainty).
1 finding from 1 review
Induction of 70‐point clinical response CDAI · induction of remission in Crohn's disease
GM‐CSF showed no clear difference in induction of 70‐point clinical response compared with placebo (low certainty).
1 finding from 1 review
Adverse events · induction of remission in Crohn's disease
GM‐CSF showed no clear difference in adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events · induction of remission in Crohn's disease
GM‐CSF showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Complete remission (CDAI<150 with a decrease in CDAI of at least 100 points from baseline) · induction of remission in Crohn's disease
IL‐10 showed no clear difference in complete remission (CDAI<150 with a decrease in CDAI of at least 100… compared with placebo (moderate certainty).
1 finding from 1 review
CDAI <150 at 24 weeks · induction of remission in Crohn's disease
IL‐10 showed no clear difference in clinical remision (CDAI<150) compared with placebo (moderate certainty).
1 finding from 1 review
Withdrawls due to adverse events · induction of remission in Crohn's disease
IL‐10 probably leads to higher withdrawls due to adverse events compared with placebo (moderate certainty).
1 finding from 1 review